The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the ...

The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s ...

Immunic Inc. (NASDAQ:IMUX) is one of the best penny stocks under $1 to buy now. On June 24, Immunic reported positive ...

Recommended initial therapy for chronic-phase (CP) chronic myeloid leukemia (CML) is imatinib 400 mg/d. 1 Imatinib has been shown to be superior to the previous standard therapy with interferon alfa ...

Background: The combination of dual immune checkpoint inhibitors (ICI) T (anti–CTLA-4) and D (anti–PD-L1) showed tolerability with a promising objective response rate (ORR) in the initial cohort of ...

Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from ...

CatalYm, today presented data from its first-in-human GDFather-1 trial (GDF-15-neutralizing antibody-mediated human effector cell relocation) at the E ...

This double-blind, randomized, placebo-controlled Phase 1 SAD study evaluated the safety, tolerability, and pharmacokinetics of TIX100 at escalating doses in 28 healthy adults.